Câncer colorretal

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colorectal cancer screening [internet publication].Texto completo

National Institute for Health and Care Excellence. Colorectal cancer. Dec 2021 [internet publication].Texto completo

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: rectal cancer [internet publication].Texto completo

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer [internet publication].Texto completo

1. Siegel RL, Wagle NS, Cercek A, et al. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023 May-Jun;73(3):233-54.Texto completo  Resumo

2. American College of Surgeons. AJCC version 9 cancer staging system. 2024 [internet publication].Texto completo

3. Eng C, Yoshino T, Ruíz-García E, et al. Colorectal cancer. Lancet. 2024 Jul 20;404(10449):294-310. Resumo

4. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Cancer stat facts: colorectal cancer. 2023 [internet publication].Texto completo

5. American Cancer Society. Cancer facts and figures 2025. 2025 [internet publication].Texto completo

6. American Cancer Society. Cancer facts and figures 2024. 2024 [internet publication].Texto completo

7. GBD 2019 Colorectal Cancer Collaborators. Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):627-47.Texto completo  Resumo

8. American Cancer Society. Colorectal cancer facts and figures, 2023-2025. 2023 [internet publication].Texto completo

9. Dai R, Kelly BN, Ike A, et al. The impact of the gut microbiome, environment, and diet in early-onset colorectal cancer development. Cancers (Basel). 2024 Feb 5;16(3):676.Texto completo  Resumo

10. Li S, Keenan JI, Shaw IC, et al. Could microplastics be a driver for early onset colorectal cancer? Cancers (Basel). 2023 Jun 24;15(13):3323.Texto completo  Resumo

11. National Bowel Cancer Audit. State of the Nation Report. Feb 2024 [internet publication].Texto completo

12. Cancer Research UK. Bowel cancer deaths could increase by 2,500 per year by 2040.​ Apr 2024 [internet publication].Texto completo

13. Fedewa SA, Flanders WD, Ward KC, et al. Racial and ethnic disparities in interval colorectal cancer incidence: a population-based cohort study. Ann Intern Med. 2017 Jun 20;166(12):857-66. Resumo

14. Parente F, Bargiggia S, Boemo C, et al. Anatomic distribution of cancers and colorectal adenomas according to age and sex and relationship between proximal and distal neoplasms in an i-FOBT-positive average-risk Italian screening cohort. Int J Colorectal Dis. 2014 Jan;29(1):57-64. Resumo

15. Kim SE, Paik HY, Yoon H, et al. Sex- and gender-specific disparities in colorectal cancer risk. World J Gastroenterol. 2015 May 7;21(17):5167-75.Texto completo  Resumo

16. Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer. 2006 Jan;42(2):216-27. Resumo

17. Song M, Emilsson L, Roelstraete B, et al. Risk of colorectal cancer in first degree relatives of patients with colorectal polyps: nationwide case-control study in Sweden. BMJ. 2021 May 4;373:n877.Texto completo  Resumo

18. Jasperson KW, Tuohy TM, Neklason DW, et al. Hereditary and familial colon cancer. Gastroenterology. 2010 Jun;138(6):2044-58.Texto completo  Resumo

19. Ma H, Brosens LA, Offerhaus GJ, et al. Pathology and genetics of hereditary colorectal cancer. Pathology. 2017 Nov 21;50(1):49-59. Resumo

20. Dong Y, Zhou J, Zhu Y, et al. Abdominal obesity and colorectal cancer risk: systematic review and meta-analysis of prospective studies. Biosci Rep. 2017 Dec 12;37(6):BSR20170945.Texto completo  Resumo

21. Wong MC, Chan CH, Cheung W, et al. Association between investigator-measured body-mass index and colorectal adenoma: a systematic review and meta-analysis of 168,201 subjects. Eur J Epidemiol. 2017 Dec 29;33(1):15-26.Texto completo  Resumo

22. Hidayat K, Yang CM, Shi BM. Body fatness at an early age and risk of colorectal cancer. Int J Cancer. 2018 Feb 15;142(4):729-40.Texto completo  Resumo

23. Mandic M, Li H, Safizadeh F, et al. Is the association of overweight and obesity with colorectal cancer underestimated? An umbrella review of systematic reviews and meta-analyses. Eur J Epidemiol. 2023 Feb;38(2):135-44.Texto completo  Resumo

24. Bardou M, Rouland A, Martel M, et al. Review article: obesity and colorectal cancer. Aliment Pharmacol Ther. 2022 Aug;56(3):407-18.Texto completo  Resumo

25. Liu PH, Wu K, Ng K, et al. Association of obesity with risk of early-onset colorectal cancer among women. JAMA Oncol. 2019 Jan 1;5(1):37-44.Texto completo  Resumo

26. Pararas N, Pikouli A, Dellaportas D, et al. The protective effect of bariatric surgery on the development of colorectal cancer: a systematic review and meta-analysis. Int J Environ Res Public Health. 2023 Feb 23;20(5):3981.Texto completo  Resumo

27. Davey MG, Ryan OK, Ryan ÉJ, et al. The impact of bariatric surgery on the incidence of colorectal cancer in patients with obesity-a systematic review and meta-analysis of registry data. Obes Surg. 2023 Aug;33(8):2293-302.Texto completo  Resumo

28. Chierici A, Amoretti P, Drai C, et al. Does bariatric surgery reduce the risk of colorectal cancer in individuals with morbid obesity? a systematic review and meta-analysis. Nutrients. 2023 Jan 16;15(2):467.Texto completo  Resumo

29. Janik MR, Clapp B, Sroczyński P, et al. The effect of bariatric surgery on reducing the risk of colorectal cancer: a meta-analysis of 3,233,044 patients. Surg Obes Relat Dis. 2023 Apr;19(4):328-34. Resumo

30. Bustamante-Lopez L, Sulbaran M, Changoor NR, et al. Impact of bariatric surgery on early-onset colorectal cancer risk: a systematic review and meta-analysis. Updates Surg. 2023 Aug;75(5):1051-7. Resumo

31. Mao Y, Pan S, Wen SW, et al; Canadian Cancer Registries Epidemiology Research Group. Physical inactivity, energy intake, obesity and the risk of rectal cancer in Canada. Int J Cancer. 2003 Jul 20;105(6):831-7. Resumo

32. Wolin KY, Yan Y, Colditz GA, Lee IM. Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer. 2009 Feb 24;100(4):611-6.Texto completo  Resumo

33. Farvid MS, Sidahmed E, Spence ND, et al. Consumption of red meat and processed meat and cancer incidence: a systematic review and meta-analysis of prospective studies. Eur J Epidemiol. 2021 Sep;36(9):937-51. Resumo

34. Bouvard V, Loomis D, Guyton KZ, et al. Carcinogenicity of consumption of red and processed meat. Lancet Oncol. 2015 Dec;16(16):1599-600. Resumo

35. Hammerling U, Bergman Laurila J, Grafström R, et al. Consumption of red/processed meat and colorectal carcinoma: possible mechanisms underlying the significant association. Crit Rev Food Sci Nutr. 2016;56(4):614-34. Resumo

36. Huang J, Pan G, Jiang H, et al. A meta-analysis between dietary carbohydrate intake and colorectal cancer risk: evidence from 17 observational studies. Biosci Rep. 2017 Apr 10;37(2):BSR20160553.Texto completo  Resumo

37. Ferguson LR, Harris PJ. The dietary fibre debate: more food for thought. Lancet. 2003 May 3;361(9368):1487-8. Resumo

38. Song M, Wu K, Meyerhardt JA, et al. Fiber intake and survival after colorectal cancer diagnosis. JAMA Oncol. 2018 Jan 1;4(1):71-9.Texto completo  Resumo

39. Ma Y, Hu M, Zhou L, et al. Dietary fiber intake and risks of proximal and distal colon cancers: a meta-analysis. Medicine (Baltimore). 2018 Sep;97(36):e11678.Texto completo  Resumo

40. Arayici ME, Mert-Ozupek N, Yalcin F, et al. Soluble and insoluble dietary fiber consumption and colorectal cancer risk: a systematic review and meta-analysis. Nutr Cancer. 2022;74(7):2412-25. Resumo

41. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colorectal cancer screening [internet publication].Texto completo

42. Chao A, Thun MJ, Jacobs EJ, et al. Cigarette smoking and colorectal cancer mortality in the cancer prevention study II. J Natl Cancer Inst. 2000 Dec 6;92(23):1888-96.Texto completo  Resumo

43. Hannan LM, Jacobs EJ, Thun MJ. The association between cigarette smoking and risk of colorectal cancer in a large prospective cohort from the United States. Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3362-7.Texto completo  Resumo

44. Fedirko V, Tramacere I, Bagnardi V, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Ann Oncol. 2011 Sep;22(9):1958-72.Texto completo  Resumo

45. O'Sullivan DE, Sutherland RL, Town S, et al. Risk factors for early-onset colorectal cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022 Jun;20(6):1229-40.e5.Texto completo  Resumo

46. Hernández-Alonso P, Boughanem H, Canudas S, et al. Circulating vitamin D levels and colorectal cancer risk: a meta-analysis and systematic review of case-control and prospective cohort studies. Crit Rev Food Sci Nutr. 2023;63(1):1-17.Texto completo  Resumo

47. Botteri E, Borroni E, Sloan EK, et al. Smoking and colorectal cancer risk, overall and by molecular subtypes: a meta-analysis. Am J Gastroenterol. 2020 Dec;115(12):1940-9. Resumo

48. Rossi M, Jahanzaib Anwar M, Usman A, et al. Colorectal cancer and alcohol consumption-populations to molecules. Cancers (Basel). 2018 Jan 30;10(2):38.Texto completo  Resumo

49. Hryhorowicz S, Kaczmarek-Ryś M, Lis-Tanaś E, et al. Strong hereditary predispositions to colorectal cancer. Genes (Basel). 2022 Dec 10;13(12):2326.Texto completo  Resumo

50. Arnold CN, Goel A, Blum HE, et al. Molecular pathogenesis of colorectal cancer. Cancer. 2005 Nov 15;104(10):2035-47.Texto completo  Resumo

51. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010 Jun;138(6):2059-72.Texto completo  Resumo

52. Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res. 2012 Mar 15;18(6):1506-12.Texto completo  Resumo

53. Nazemalhosseini Mojarad E, Kuppen PJ, Aghdaei HA, et al. The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterol Hepatol Bed Bench. 2013 Summer;6(3):120-8.Texto completo  Resumo

54. Plawski A, Banasiewicz T, Borun P et al. Familial adenomatous polyposis of the colon. Hered Cancer Clin Pract. 2013 Oct 22;11:15.Texto completo

55. Parker TW, Neufeld KL. APC controls Wnt-induced β-catenin destruction complex recruitment in human colonocytes. Sci Rep. 2020 Feb 19;10(1):2957.Texto completo  Resumo

56. Saravani K, Salarzaei M, Parooie F. Effect of KRAS and BRAF mutations in metastatic colorectal cancer patients: a systematic review and meta-analysis based on tumor sidedness and KRAS subtypes. Hum Antibodies. 2021;29(4):275-84.Texto completo  Resumo

57. Strickler JH, Yoshino T, Stevinson K, et al. Prevalence of KRAS G12C mutation and co-mutations and associated clinical outcomes in patients with colorectal cancer: a systematic literature review. Oncologist. 2023 Nov 2;28(11):e981-94.Texto completo  Resumo

58. Christensen TD, Spindler KL, Palshof JA, et al. Systematic review: brain metastases from colorectal cancer - incidence and patient characteristics. BMC Cancer. 2016 Apr 1;16:260.Texto completo  Resumo

59. Raphael MJ, Karanicolas PJ. Regional therapy for colorectal cancer liver metastases: which modality and when? J Clin Oncol. 2022 Aug 20;40(24):2806-17.Texto completo  Resumo

60. Issaka RB, Chan AT, Gupta S. AGA clinical practice update on risk stratification for colorectal cancer screening and post-polypectomy surveillance: expert review. Gastroenterology. 2023 Nov;165(5):1280-91.Texto completo  Resumo

61. American College of Obstetricians and Gynecologists. Practice bulletin no. 147: lynch syndrome. Nov 2014 [internet publication].Texto completo

62. Peltomäki P, Nyström M, Mecklin JP, et al. Lynch syndrome genetics and clinical implications. Gastroenterology. 2023 Apr;164(5):783-99.Texto completo  Resumo

63. Hornbuckle K, Fritz CDL. What is lynch syndrome? JAMA. 2024 Jul 9;332(2):178.Texto completo  Resumo

64. Meyers M, Theodosiou M, Acharya S, et al. Cell cycle regulation of the human DNA mismatch repair genes hMSH2, hMLH1, and hPMS2. Cancer Res. 1997 Jan 15;57(2):206-8. Resumo

65. Wang Q, Lasset C, Desseigne F, et al. Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer. Hum Genet. 1999 Jul-Aug;105(1-2):79-85. Resumo

66. Fu L, Sheng JQ, Li XO, et al. Mismatch repair gene mutation analysis and colonoscopy surveillance in Chinese Lynch syndrome families. Cell Oncol (Dordr). 2013 Jun;36(3):225-31. Resumo

67. De Jong AE, Morreau H, Van Puijenbroek M, et al. The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology. 2004 Jan;126(1):42-8. Resumo

68. Yamamoto H, Imai K. Microsatellite instability: an update. Arch Toxicol. 2015 Feb 22;89(6):899-921. Resumo

69. Nielsen M, Morreau H, Vasen HF, et al. MUTYH-associated polyposis (MAP). Crit Rev Oncol Hematol. 2011 Jul;79(1):1-16. Resumo

70. Kidambi TD, Kohli DR, Samadder NJ, et al. Hereditary polyposis syndromes. Curr Treat Options Gastroenterol. 2019 Dec;17(4):650-65. Resumo

71. Giardiello FM, Bresinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000 Dec;119(6):1447-53. Resumo

72. Bopanna S, Ananthakrishnan AN, Kedia S, et al. Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017 Feb 21;2(4):269-76.Texto completo  Resumo

73. Castaño-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther. 2014 Apr;39(7):645-59.Texto completo  Resumo

74. Jess T, Gamborg M, Matzen P, et al. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005 Dec;100(12):2724-9. Resumo

75. Gilat T, Fireman Z, Grossman A, et al. Colorectal cancer in patients with ulcerative colitis. A population study in central Israel. Gastroenterology. 1988 Apr;94(4):870-7. Resumo

76. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001 Apr;48(4):526-35.Texto completo  Resumo

77. Dworakowska D, Grossman AB. Colonic cancer and acromegaly. Front Endocrinol (Lausanne). 2019;10:390.Texto completo  Resumo

78. Dal J, Leisner MZ, Hermansen K, et al. Cancer incidence in patients with acromegaly: a cohort study and meta-analysis of the literature. J Clin Endocrinol Metab. 2018 Jun 1;103(6):2182-8.Texto completo  Resumo

79. Kruk J, Aboul-Enein HY. Physical activity and cancer prevention: updating the evidence. The role of oxidative stress in carcinogenesis. Curr Cancer Ther Rev. 2007;3(2):81-95.

80. Wu W, Guo F, Ye J, et al. Pre- and post-diagnosis physical activity is associated with survival benefits of colorectal cancer patients: a systematic review and meta-analysis. Oncotarget. 2016 Aug 9;7(32):52095-103.Texto completo  Resumo

81. Shami JJP, Zhao J, Pathadka S, et al. Safety and effectiveness of low-dose aspirin for the prevention of gastrointestinal cancer in adults without atherosclerotic cardiovascular disease: a population-based cohort study. BMJ Open. 2022 Feb 4;12(2):e050510.Texto completo  Resumo

82. Sikavi DR, Wang K, Ma W, et al. Aspirin use and incidence of colorectal cancer according to lifestyle risk. JAMA Oncol. 2024 Oct 1;10(10):1354-61. Resumo

83. Lloyd KE, Hall LH, King N, et al. Aspirin use for cancer prevention: a systematic review of public, patient and healthcare provider attitudes and adherence behaviours. Prev Med. 2022 Jan;154:106872.Texto completo  Resumo

84. Guo CG, Ma W, Drew DA, et al. Aspirin use and risk of colorectal cancer among older adults. JAMA Oncol. 2021 Mar 1;7(3):428-35.Texto completo  Resumo

85. Guirguis-Blake JM, Evans CV, Perdue LA, et al. Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022 Apr 26;327(16):1585-97.Texto completo  Resumo

86. Shaukat A, Kahi CJ, Burke CA, et al. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol. 2021 Mar 1;116(3):458-79.Texto completo  Resumo

87. Cook NR, Lee IM, Zhang SM, et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013 Jul 16;159(2):77-85.Texto completo  Resumo

88. Emilsson L, Holme Ø, Bretthauer M, et al. Systematic review with meta-analysis: the comparative effectiveness of aspirin vs. screening for colorectal cancer prevention. Aliment Pharmacol Ther. 2017 Jan;45(2):193-204.Texto completo  Resumo

89. Giorli G, Rouette J, Yin H, et al. Prediagnostic use of low-dose aspirin and risk of incident metastasis and all-cause mortality among patients with colorectal cancer. Br J Clin Pharmacol. 2020 Nov;86(11):2266-73.Texto completo  Resumo

90. Nishihara R, Lochhead P, Kuchiba A, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013 Jun 26;309(24):2563-71.Texto completo  Resumo

91. National Institute for Health and Care Excellence. Colorectal cancer. Dec 2021 [internet publication].Texto completo

92. Burn J, Sheth H, Elliott F, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020 Jun 13;395(10240):1855-63.Texto completo  Resumo

93. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: colorectal, endometrial, and gastric [internet publication].Texto completo

94. Tomić T, Domínguez-López S, Barrios-Rodríguez R. Non-aspirin non-steroidal anti-inflammatory drugs in prevention of colorectal cancer in people aged 40 or older: a systematic review and meta-analysis. Cancer Epidemiol. 2019 Feb;58:52-62. Resumo

95. Liang PS, Shaukat A, Crockett SD. AGA clinical practice update on chemoprevention for colorectal neoplasia: expert review. Clin Gastroenterol Hepatol. 2021 Jul;19(7):1327-36.Texto completo  Resumo

96. Rostom A, Dubé C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007 Mar 6;146(5):376-89.Texto completo  Resumo

97. Kim J, Boushey CJ, Wilkens LR, et al. Plant-based dietary patterns defined by a priori indices and colorectal cancer risk by sex and race/ethnicity: the multiethnic cohort study. BMC Med. 2022 Nov 29;20(1):430.Texto completo  Resumo

98. Liu F, Lv Y, Peng Y, et al. Plant-based dietary patterns, genetic predisposition and risk of colorectal cancer: a prospective study from the UK Biobank. J Transl Med. 2023 Sep 27;21(1):669.Texto completo  Resumo

99. Wang F, Ugai T, Haruki K, et al. Healthy and unhealthy plant-based diets in relation to the incidence of colorectal cancer overall and by molecular subtypes. Clin Transl Med. 2022 Aug;12(8):e893.Texto completo  Resumo

100. Ben S, Du M, Ma G, et al. Vitamin B2 intake reduces the risk for colorectal cancer: a dose-response analysis. Eur J Nutr. 2019 Jun;58(4):1591-602. Resumo

101. Fu H, He J, Li C, et al. Folate intake and risk of colorectal cancer: a systematic review and up-to-date meta-analysis of prospective studies. Eur J Cancer Prev. 2023 Mar 1;32(2):103-12. Resumo

102. Aglago EK, Huybrechts I, Murphy N, et al. Consumption of fish and long-chain n-3 polyunsaturated fatty acids is associated with reduced risk of colorectal cancer in a large European cohort. Clin Gastroenterol Hepatol. 2020 Mar;18(3):654-66.e6.Texto completo  Resumo

103. Li L, Wang D, He N, et al. Effects of polyunsaturated fatty acids on colorectal cancer patients: a meta-analysis of randomized controlled trials. Nutr Cancer. 2023;75(2):627-39.Texto completo  Resumo

104. Cruz-Pierard SM, Nestares T, Amaro-Gahete FJ. Vitamin D and calcium as key potential factors related to colorectal cancer prevention and treatment: a systematic review. Nutrients. 2022 Nov 21;14(22):4934.Texto completo  Resumo

105. Emami MH, Salehi M, Hassanzadeh Keshteli A, et al. Calcium and dairy products in the chemoprevention of colorectal adenomas: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2022;62(26):7168-83. Resumo

106. Lopez-Caleya JF, Ortega-Valín L, Fernández-Villa T, et al. The role of calcium and vitamin D dietary intake on risk of colorectal cancer: systematic review and meta-analysis of case-control studies. Cancer Causes Control. 2022 Feb;33(2):167-82. Resumo

107. Ma Y, You W, Cao Y, et al. Chemoprevention of colorectal cancer in general population and high-risk population: a systematic review and network meta-analysis. Chin Med J (Engl). 2023 Apr 5;136(7):788-98.Texto completo  Resumo

108. Emmanouilidou G, Kalopitas G, Bakaloudi DR, et al. Vitamin D as a chemopreventive agent in colorectal neoplasms. a systematic review and meta-analysis of randomized controlled trials. Pharmacol Ther. 2022 Sep;237:108252. Resumo

109. Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012 Feb 23;366(8):687-96.Texto completo  Resumo

110. Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017 Jun 6;112(7):1016-30.Texto completo  Resumo

111. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. Aug 2023 [internet publication].Texto completo

112. Rockey DC, Cello JP. Evaluation of the gastrointestinal tract in patients with iron-deficiency anemia. N Engl J Med. 1993 Dec 2;329(23):1691-5.Texto completo  Resumo

113. Raje D, Mukhtar H, Oshowo A, et al. What proportion of patients referred to secondary care with iron deficiency anemia have colon cancer? Dis Colon Rectum. 2007 Aug;50(8):1211-4. Resumo

114. Atkin W, Dadswell E, Wooldrage K, et al; SIGGAR Investigators. Computed tomographic colonography versus colonoscopy for investigation of patients with symptoms suggestive of colorectal cancer (SIGGAR): a multicentre randomised trial. Lancet. 2013 Apr 6;381(9873):1194-202. Resumo

115. Vogel JD, Felder SI, Bhama AR, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of colon cancer. Dis Colon Rectum. 2022 Feb 1;65(2):148-77.Texto completo  Resumo

116. Bressler B, Paszat LF, Chen Z, et al. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology. 2007 Jan;132(1):96-102. Resumo

117. Lieberman DA, Weiss DG, Bond JH, et al; Veterans Affairs Cooperative Study Group 380. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. N Engl J Med. 2000 Jul 20;343(3):162-8.Texto completo  Resumo

118. Luning T, Keemers-Gels M, Barendregt W, et al. Colonoscopic perforations: a review of 30,366 patients. Surg Endosc. 2007 Jun;21(6):994-7. Resumo

119. Holme Ø, Bretthauer M, Fretheim A, et al. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev. 2013 Oct 1;(9):CD009259.Texto completo  Resumo

120. Zhang C, Liu L, Li J, et al. Effect of flexible sigmoidoscopy-based screening on colorectal cancer incidence and mortality: an updated systematic review and meta-analysis of randomized controlled trials. Expert Rev Anticancer Ther. 2023 Jul-Dec;23(11):1217-27. Resumo

121. Gluecker TM, Johnson CD, Harmsen WS, et al. Colorectal cancer screening with CT colonography, colonoscopy, and double-contrast barium enema examination: prospective assessment of patient perceptions and preferences. Radiology. 2003 May;227(2):378-84. Resumo

122. Bosworth HB, Rockey DC, Paulson EK, et al. Prospective comparison of patient experience with colon imaging tests. Am J Med. 2006 Sep;119(9):791-9. Resumo

123. Halligan S, Wooldrage K, Dadswell E, et al; SIGGAR investigators. Computed tomographic colonography versus barium enema for diagnosis of colorectal cancer or large polyps in symptomatic patients (SIGGAR): a multicentre randomised trial. Lancet. 2013 Apr 6;381(9873):1185-93. Resumo

124. von Wagner C, Smith S, Halligan S, et al. Patient acceptability of CT colonography compared with double contrast barium enema: results from a multicentre randomised controlled trial of symptomatic patients. Eur Radiol. 2011 May 31;21(10):2046-55. Resumo

125. Rex DK, Rahmani EY, Haseman JH, et al. Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology. 1997 Jan;112(1):17-23. Resumo

126. Rockey RC, Paulson E, Niedzwiecki D, et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet. 2005 Jan 22-28;365(9456):305-11. Resumo

127. Mulhall BP, Veerappan GR, Jackson JL. Meta-analysis: computed tomographic colonography. Ann Intern Med. 2005 Apr 19;142(8):635-50.Texto completo  Resumo

128. Glynne-Jones L, Wyrwicz E, Tiret G, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv22-iv40.Texto completo

129. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: rectal cancer [internet publication].Texto completo

130. Al-Sukhni E, Milot L, Fruitman M, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2012 Jul;19(7):2212-23. Resumo

131. Watson AJ, Lolohea S, Robertson GM, et al. The role of positron emission tomography in the management of recurrent colorectal cancer: a review. Dis Colon Rectum. 2007 Jan;50(1):102-14. Resumo

132. Zhang C, Chen Y, Xue H, et al. Diagnostic value of FDG-PET in recurrent colorectal carcinoma: a meta-analysis. Int J Cancer. 2009 Jan 1;124(1):167-73. Resumo

133. Facey K, Bradbury I, Laking G, et al. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess. 2007 Oct;11(44):iii-iv, xi-267.Texto completo  Resumo

134. Moulton CA, Gu CS, Law CH, et al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA. 2014 May 14;311(18):1863-9.Texto completo  Resumo

135. Flamen P, Hoekstra OS, Homans F, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer. 2001 May;37(7):862-9. Resumo

136. Royal College of Radiologists, Royal College of Physicians. Evidence-based indications for the use of PET-CT in the United Kingdom 2022 [internet publication].Texto completo

137. Yu T, Meng N, Chi D, et al. Diagnostic value of (18)F-FDG PET/CT in detecting local recurrent colorectal cancer: a pooled analysis of 26 individual studies. Cell Biochem Biophys. 2015 Jun;72(2):443-51. Resumo

138. National Institute for Health and Care Excellence. Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care. Aug 2023 [internet publication].Texto completo

139. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer [internet publication].Texto completo

140. National Institute for Health and Care Excellence. Colorectal cancer. Quality standard (QS20). Feb 2022 [internet publication].Texto completo

141. Lieberman DA, AGA CRC Workshop Panel. Commentary: liquid biopsy for average-risk colorectal cancer screening. Clin Gastroenterol Hepatol. 2024 Jun;22(6):1160-4.e1. Resumo

142. Chung DC, Gray DM 2nd, Singh H, et al. A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med. 2024 Mar 14;390(11):973-83.Texto completo  Resumo

143. Ladabaum U, Mannalithara A, Weng Y, et al. Comparative effectiveness and cost-effectiveness of colorectal cancer screening with blood-based biomarkers (liquid biopsy) vs fecal tests or colonoscopy. Gastroenterology. 2024 Jul;167(2):378-91. Resumo

144. van den Puttelaar R, Nascimento de Lima P, Knudsen AB, et al. Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With a Blood Test That Meets the Centers for Medicare & Medicaid Services coverage decision. Gastroenterology. 2024 Jul;167(2):368-77.Texto completo  Resumo

145. Burke CA, Lieberman D, Feuerstein JD. AGA Clinical practice update on approach to the use of noninvasive colorectal cancer screening options: commentary. Gastroenterology. 2022 Mar;162(3):952-6.Texto completo  Resumo

146. du Toit J, Hamilton W, Barraclough K. Risk in primary care of colorectal cancer from new onset rectal bleeding: 10 year prospective study. BMJ. 2006 Jul 8;333(7558):69-70. Resumo

147. McSherry CK, Cornell GN, Glenn F. Carcinoma of the colon and rectum. Ann Surg. 1969 Apr;169(4):502-9. Resumo

148. Shallow TA, Wagner FB, Colcher RE. Clinical evaluation of 750 patients with colon cancer. Diagnostic survey and follow up covering a 15 year period. Ann Surg. 1955 Aug;142(2):164-75. Resumo

149. Holtedahl K, Borgquist L, Donker GA, et al. Symptoms and signs of colorectal cancer, with differences between proximal and distal colon cancer: a prospective cohort study of diagnostic accuracy in primary care. BMC Fam Pract. 2021 Jul 8;22(1):148.Texto completo  Resumo

150. Kanellos D, Kitsios G, Kanellos I, et al. Anemia as a symptom of right colon cancer. Tech Coloproctol. 2004 Nov;8 Suppl 1:s62-4. Resumo

151. Maas MHJ, Neumann H, Shirin H, et al. A computer-aided polyp detection system in screening and surveillance colonoscopy: an international, multicentre, randomised, tandem trial. Lancet Digit Health. 2024 Mar;6(3):e157-65.Texto completo  Resumo

152. Hassan C, Spadaccini M, Mori Y, et al. Real-time computer-aided detection of colorectal neoplasia during colonoscopy: a systematic review and meta-analysis. Ann Intern Med. 2023 Sep;176(9):1209-20. Resumo

153. Thoeni RF. Colorectal cancer. Radiologic staging. Radiol Clin North Am. 1997 Mar;35(2):457-85. Resumo

154. Scott AJ, Kennedy EB, Berlin J, et al. Management of locally advanced rectal cancer: ASCO guideline. J Clin Oncol. 2024 Oct;42(28):3355-75.Texto completo  Resumo

155. Kwok H, Bissett IP, Hill GL. Preoperative staging of rectal cancer. Int J Colorectal Dis. 2000 Feb;15(1):9-20. Resumo

156. Nikolaou S, Qiu S, Fiorentino F, et al. Systematic review of blood diagnostic markers in colorectal cancer. Tech Coloproctol. 2018 Jul 18;22(7):481-98.Texto completo  Resumo

157. Nicholson BD, Shinkins B, Pathiraja I, et al. Blood CEA levels for detecting recurrent colorectal cancer. Cochrane Database Syst Rev. 2015 Dec 10;(12):CD011134.Texto completo  Resumo

158. Shinkins B, Nicholson BD, James T, et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial. Health Technol Assess. 2017 Apr;21(22):1-60.Texto completo  Resumo

159. Backes Y, Moss A, Reitsma JB, et al. Narrow band imaging, magnifying chromoendoscopy, and gross morphological features for the optical diagnosis of T1 colorectal cancer and deep submucosal invasion: a systematic review and meta-analysis. Am J Gastroenterol. 2016 Sep 20;112(1):54-64. Resumo

160. Fan X, Zhang J, Lu D. CtDNA's prognostic value in patients with early-stage colorectal cancer after surgery: a meta-analysis and systematic review. Medicine (Baltimore). 2023 Feb 10;102(6):e32939.Texto completo  Resumo

161. Faulkner LG, Howells LM, Pepper C, et al. The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis. Br J Cancer. 2023 Jan;128(2):297-309.Texto completo  Resumo

162. Mi J, Wang R, Han X, et al. Treatment stratification and prognosis assessment using circulating tumor DNA in locally advanced rectal cancer: a systematic review and meta-analysis. Cancer Med. 2023 Sep;12(17):17934-44.Texto completo  Resumo

163. Wullaert L, van Rees JM, Martens JWM, et al. Circulating tumour DNA as biomarker for colorectal liver metastases: a systematic review and meta-analysis. Cells. 2023 Oct 25;12(21):2520.Texto completo  Resumo

164. Loft M, To YH, Gibbs P, et al. Clinical application of circulating tumour DNA in colorectal cancer. Lancet Gastroenterol Hepatol. 2023 Sep;8(9):837-52. Resumo

165. Dawood ZS, Alaimo L, Lima HA, et al. Circulating tumor DNA, imaging, and carcinoembryonic antigen: comparison of surveillance strategies among patients who underwent resection of colorectal cancer-a systematic review and meta-analysis. Ann Surg Oncol. 2023 Jan;30(1):259-74. Resumo

166. Chidharla A, Rapoport E, Agarwal K, et al. Circulating tumor DNA as a minimal residual disease assessment and recurrence risk in patients undergoing curative-intent resection with or without adjuvant chemotherapy in colorectal cancer: a systematic review and meta-analysis. Int J Mol Sci. 2023 Jun 16;24(12):10230.Texto completo  Resumo

167. Bratman SV, Yang SYC, Iafolla MAJ, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020 Sep;1(9):873-81. Resumo

168. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016 May;150(6):1393-407. Resumo

169. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002 Dec;123(6):2108-31.Texto completo  Resumo

170. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011 May;140(6):1785-94.Texto completo  Resumo

171. Shergill AK, Lightdale JR, Bruining DH, et al; American Society for Gastrointestinal Endoscopy Standards of Practice Committee. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015 Mar 20;81(5):1101-21.e1-13.Texto completo  Resumo

172. Public Health England. Bowel cancer screening: programme overview. Mar 2021 [internet publication].Texto completo

173. NHS England. NHS checks for bowel cancer hit record-high thanks to Dame Deborah.​ Aug 2022 [internet publication].Texto completo

174. NHS England. Thousands with cancer-causing condition offered life-saving NHS bowel cancer screening. Feb 2024 [internet publication].Texto completo

175. NHS England. NHS launches tool to improve bowel cancer screening for people with sight loss. May 2024 [internet publication].Texto completo

176. US Preventive Services Task Force., Davidson KW, Barry MJ, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021 May 18;325(19):1965-77.Texto completo  Resumo

177. Lieberman D, Ladabaum U, Brill JV, et al. Reducing the burden of colorectal cancer: AGA position statements. Gastroenterology. 2022 Aug;163(2):520-6.Texto completo  Resumo

178. Patel SG, May FP, Anderson JC, et al. Updates on age to start and stop colorectal cancer screening: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2022 Jan 1;117(1):57-69.Texto completo  Resumo

179. Wolf AM, Fontham ET, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018 May 30;68(4):250-81.Texto completo  Resumo

180. Qaseem A, Harrod CS, Crandall CJ, et al. Screening for colorectal cancer in asymptomatic average-risk adults: a guidance statement from the American College of Physicians (version 2). Ann Intern Med. 2023 Aug;176(8):1092-100.Texto completo  Resumo

181. NEJM Journal Watch. The American College of Physicians weighs in on colorectal cancer screening. Aug 2023 [internet publication].​

182. Canadian Task Force on Preventive Health Care. Recommendations on screening for colorectal cancer in primary care. CMAJ. 2016 Mar 15;188(5):340-8.Texto completo  Resumo

183. Buskermolen M, Cenin DR, Helsingen LM, et al. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. BMJ. 2019 Oct 2;367:l5383.Texto completo  Resumo

184. Cairns SR, Scholefield JH, Steele RJ, et al; British Society of Gastroenterology; Association of Coloproctology for Great Britain and Ireland. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010 May;59(5):666-89. Resumo

185. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015 Feb 3;110(2):223-62.Texto completo  Resumo

186. Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Dis Colon Rectum. 2014 Aug;57(8):1025-48. Resumo

187. Boland CR, Idos GE, Durno C, et al. Diagnosis and management of cancer risk in the gastrointestinal hamartomatous polyposis syndromes: recommendations from the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2022 Jun 1;117(6):846-64.Texto completo  Resumo

188. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019 Mar;114(3):384-413.Texto completo  Resumo

189. Murthy SK, Feuerstein JD, Nguyen GC, et al. AGA clinical practice update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: expert review. Gastroenterology. 2021 Sep;161(3):1043-51.e4.Texto completo  Resumo

190. van Gijn W, Gooiker GA, Wouters MW, et al. Volume and outcome in colorectal cancer surgery. Eur J Surg Oncol. 2010;36(suppl 1):S55-S63. Resumo

191. Molenaar CJ, van Rooijen SJ, Fokkenrood HJ, et al. Prehabilitation versus no prehabilitation to improve functional capacity, reduce postoperative complications and improve quality of life in colorectal cancer surgery. Cochrane Database Syst Rev. 2022 May 19;5(5):CD013259.Texto completo  Resumo

192. Molenaar CJL, Minnella EM, Coca-Martinez M, et al. Effect of multimodal prehabilitation on reducing postoperative complications and enhancing functional capacity following colorectal cancer surgery: the PREHAB randomized clinical trial. JAMA Surg. 2023 Jun 1;158(6):572-81.Texto completo  Resumo

193. Cheng H, Zhou M, Yang L, et al. The impact of laparoscopic, open, extended right, and left colectomy on clinical outcomes of splenic flexure colon cancer: a meta-analysis. Medicine (Baltimore). 2023 May 12;102(19):e33742.Texto completo  Resumo

194. Kampman SL, Smalbroek BP, Dijksman LM, et al. Postoperative inflammatory response in colorectal cancer surgery: a meta-analysis. Int J Colorectal Dis. 2023 Sep 19;38(1):233. Resumo

195. Nelson H, Sargent DJ, Wieand HS, et al; Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004 May 13;350(20):2050-9.Texto completo  Resumo

196. Buunen M, Veldkamp R, Hop WC, et al; Colon Cancer Laparoscopic or Open Resection Study Group. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol. 2009 Jan;10(1):44-52. Resumo

197. Green BL, Marshall HC, Collinson F, et al. Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer. Br J Surg. 2013 Jan;100(1):75-82.Texto completo  Resumo

198. Kennedy RH, Francis EA, Wharton R, et al. Multicenter randomized controlled trial of conventional versus laparoscopic surgery for colorectal cancer within an enhanced recovery programme: EnROL. J Clin Oncol. 2014 Jun 10;32(17):1804-11.Texto completo  Resumo

199. Cui M, Liu S. Meta-analysis of the effect of laparoscopic surgery and open surgery on long-term quality of life in patients with colorectal cancer. Medicine (Baltimore). 2023 Sep 8;102(36):e34922.Texto completo  Resumo

200. Lai JH, Law WL. Laparoscopic surgery for colorectal cancer. Br Med Bull. 2012 Oct 19;104:61-89.Texto completo  Resumo

201. Anderson C, Uman G, Pigazzi A. Oncologic outcomes of laparoscopic surgery for rectal cancer: a systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2008 Oct;34(10):1135-42. Resumo

202. Ng SS, Lee JF, Yiu RY, et al. Long-term oncologic outcomes of laparoscopic versus open surgery for rectal cancer: a pooled analysis of 3 randomized controlled trials. Ann Surg. 2014 Jan;259(1):139-47. Resumo

203. Vennix S, Pelzers L, Bouvy N, et al. Laparoscopic versus open total mesorectal excision for rectal cancer. Cochrane Database Syst Rev. 2014 Apr 15;(4):CD005200.Texto completo  Resumo

204. Bonjer HJ, Deijen CL, Abis GA, et al; COLOR II Study Group. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med. 2015 Apr 2;372(14):1324-32.Texto completo  Resumo

205. Jeong SY, Park JW, Nam BH, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol. 2014 Jun;15(7):767-74. Resumo

206. Fleshman J, Branda M, Sargent DJ, et al. Effect of laparoscopic-assisted resection vs. open resection of stage II or III rectal cancer on pathologic outcomes: the ACOSOG Z6051 randomized clinical trial. JAMA. 2015 Oct 6;314(13):1346-55. Resumo

207. Prete FP, Pezzolla A, Prete F, et al. Robotic versus laparoscopic minimally invasive surgery for rectal cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Surg. 2018 Jun;267(6):1034-46. Resumo

208. Holmer C, Kreis ME. Systematic review of robotic low anterior resection for rectal cancer. Surg Endosc. 2017 Dec 7;32(2):569-81. Resumo

209. Lee SH, Kim DH, Lim SW. Robotic versus laparoscopic intersphincteric resection for low rectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2018 Sep 5;33(12):1741-53. Resumo

210. Martins RS, Fatimi AS, Mahmud O, et al. Multidimensional quality of life after robotic versus laparoscopic surgery for rectal cancer: a systematic review and meta-analysis. World J Surg. 2023 May;47(5):1310-9. Resumo

211. Seow W, Dudi-Venkata NN, Bedrikovetski S, et al. Outcomes of open vs laparoscopic vs robotic vs transanal total mesorectal excision (TME) for rectal cancer: a network meta-analysis. Tech Coloproctol. 2023 May;27(5):345-60. Resumo

212. Li X, Liu ZH, Wang N, et al. Robotic versus laparoscopic total mesorectal excision for rectal cancer: a meta-analysis of long-term survival and urogenital functional outcomes. Minerva Gastroenterol (Torino). 2023 Sep;69(3):403-11. Resumo

213. Jayne D, Pigazzi A, Marshall H, et al. Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. JAMA. 2017 Oct 24;318(16):1569-80.Texto completo  Resumo

214. Spanjersberg WR, Reurings J, Keus F, et al. Fast track surgery versus conventional recovery strategies for colorectal surgery. Cochrane Database Syst Rev. 2011 Feb 16;(2):CD007635.Texto completo  Resumo

215. van der Pas MH, Haglind E, Cuesta MA, et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol. 2013 Mar;14(3):210-8. Resumo

216. Li N, Liu Y, Chen H, et al. Efficacy and safety of enhanced recovery after surgery pathway in minimally invasive colorectal cancer surgery: a systemic review and meta-analysis. J Laparoendosc Adv Surg Tech A. 2023 Feb;33(2):177-87. Resumo

217. Sajid MS, Farag S, Leung P, et al. Systematic review and meta-analysis of published trials comparing the effectiveness of transanal endoscopic microsurgery and radical resection in the management of early rectal cancer. Colorectal Dis. 2014 Jan;16(1):2-14. Resumo

218. Sgourakis G, Lanitis S, Gockel I, et al. Transanal endoscopic microsurgery for T1 and T2 rectal cancers: a meta-analysis and meta-regression analysis of outcomes. Am Surg. 2011 Jun;77(6):761-72. Resumo

219. Clancy C, Burke JP, Albert MR, et al. Transanal endoscopic microsurgery versus standard transanal excision for the removal of rectal neoplasms: a systematic review and meta-analysis. Dis Colon Rectum. 2015 Feb;58(2):254-61. Resumo

220. Kim M, Bareket R, Eleftheriadis NP, et al. Endoscopic submucosal dissection (ESD) offers a safer and more cost-effective alternative to transanal endoscopic microsurgery (TEM): an international collaborative study. J Clin Gastroenterol. 2023 May-Jun 01;57(5):486-9. Resumo

221. Kiriyama S, Saito Y, Matsuda T, et al. Comparing endoscopic submucosal dissection with transanal resection for non-invasive rectal tumor: a retrospective study. J Gastroenterol Hepatol. 2011 Jun;26(6):1028-33. Resumo

222. Park SU, Min YW, Shin JU, et al. Endoscopic submucosal dissection or transanal endoscopic microsurgery for nonpolypoid rectal high grade dysplasia and submucosa-invading rectal cancer. Endoscopy. 2012 Nov;44(11):1031-6. Resumo

223. Bax TW, McNevin MS. The value of diverting loop ileostomy on the high-risk colon and rectal anastomosis. Am J Surg. 2007 May;193(5):585-7; discussion 587-8. Resumo

224. Hanna MH, Vinci A, Pigazzi A. Diverting ileostomy in colorectal surgery: when is it necessary? Langenbecks Arch Surg. 2015 Feb;400(2):145-52. Resumo

225. Lynn PB, Renfro LA, Carrero XW, et al. Anorectal function and quality of life in patients with early stage rectal cancer treated with chemoradiation and local excision. Dis Colon Rectum. 2017 May;60(5):459-68. Resumo

226. Rödel C, Liersch T, Becker H, et al; German Rectal Cancer Study Group. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012 Jul;13(7):679-87. Resumo

227. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012 Jun 1;30(16):1926-33. Resumo

228. Fiorica F, Cartei F, Licata A, et al. Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data. Cancer Treat Rev. 2010 Nov;36(7):539-49. Resumo

229. Tiv M, Puyraveau M, Mineur L, et al. Long-term quality of life in patients with rectal cancer treated with preoperative (chemo)-radiotherapy within a randomized trial. Cancer Radiother. 2010 Oct;14(6-7):530-4. Resumo

230. Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 May;22(5):702-15. Resumo

231. van Gijn W, Marijnen CA, Nagtegaal ID, et al; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011 Jun;12(6):575-82. Resumo

232. Pettersson D, Cedermark B, Holm T, et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg. 2010 Apr;97(4):580-7. Resumo

233. Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012 Nov 1;30(31):3827-33. Resumo

234. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol. 2004 Jul;72(1):15-24. Resumo

235. Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Jan;22(1):29-42. Resumo

236. Dijkstra EA, Nilsson PJ, Hospers GAP, et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-Year follow-up of the RAPIDO trial. Ann Surg. 2023 Oct 1;278(4):e766-72.Texto completo  Resumo

237. ClinicalTrials.gov. Short RT versus RCT,followed by chemo.and organ preservation for interm and high-risk rectal cancer patients. ClinicalTrials.gov Identifier: NCT04246684. Sep 2019 [internet publication]​.Texto completo

238. van den Broek CB, Vermeer TA, Bastiaannet E, et al. Impact of the interval between short-course radiotherapy and surgery on outcomes of rectal cancer patients. Eur J Cancer. 2013 Oct;49(15):3131-9.Texto completo  Resumo

239. Erlandsson J, Holm T, Pettersson D, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017 Mar;18(3):336-46. Resumo

240. Wo JY, Ashman JB, Bhadkamkar NA, et al. Radiation therapy for rectal cancer: an ASTRO clinical practice guideline focused update. Pract Radiat Oncol. 25 Nov 2024 [Epub ahead of print].Texto completo  Resumo

241. Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol. 2010 Sep;21(9):1743-50.Texto completo  Resumo

242. Bosset JF, Calais G, Mineur L, et al; EORTC Radiation Oncology Group. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014 Feb;15(2):184-90. Resumo

243. Cancer Care Ontario. Preoperative or postoperative therapy for the management of patients with stage II or III rectal cancer. Mar 2019 [internet publication].Texto completo

244. Hong YS, Kim SY, Lee JS, et al. Oxaliplatin-based adjuvant chemotherapy for rectal cancer after preoperative chemoradiotherapy (ADORE): long-term results of a randomized controlled trial. J Clin Oncol. 2019 Nov 20;37(33):3111-23.Texto completo  Resumo

245. Kim TW, Lee JH, Lee JH, et al. Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: 10-year follow-up. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1025-31. Resumo

246. Zhang X, Ma S, Guo Y, et al. Total neoadjuvant therapy versus standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis of 15 trials. PLoS One. 2022;17(11):e0276599.Texto completo  Resumo

247. Cercek A, Roxburgh CSD, Strombom P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018 Jun 14;4(6):e180071.Texto completo  Resumo

248. de Mestier L, Manceau G, Neuzillet C, et al. Primary tumor resection in colorectal cancer with unresectable synchronous metastases: a review. World J Gastrointest Oncol. 2014 Jun 15;6(6):156-69.Texto completo  Resumo

249. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002 Jun;235(6):759-66.Texto completo  Resumo

250. Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer. 2007 Feb 15;109(4):718-26.Texto completo  Resumo

251. Cao G, Cheng D, Ye L, et al. Surgical resection of pulmonary metastases from colorectal cancer: 11 years of experiences. PLoS One. 2017 Apr 10;12(4):e0175284.Texto completo  Resumo

252. Groot Koerkamp B, Sadot E, Kemeny NE, et al. Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: a propensity score analysis. J Clin Oncol. 2017 Jun 10;35(17):1938-44.Texto completo  Resumo

253. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004 Jun;15(6):933-9.Texto completo  Resumo

254. Ozair A, Collings A, Adams AM, et al. Minimally invasive versus open hepatectomy for the resection of colorectal liver metastases: a systematic review and meta-analysis. Surg Endosc. 2022 Nov;36(11):7915-37. Resumo

255. Vreeland TJ, Collings AT, Ozair A, et al. SAGES/AHPBA guidelines for the use of minimally invasive surgery for the surgical treatment of colorectal liver metastases (CRLM). Surg Endosc. 2023 Apr;37(4):2508-16. Resumo

256. Petrelli F, Comito T, Barni S, et al. Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review. Radiother Oncol. 2018 Dec;129(3):427-34. Resumo

257. Abdalla M, Collings AT, Dirks R, et al. Surgical approach to microwave and radiofrequency liver ablation for hepatocellular carcinoma and colorectal liver metastases less than 5 cm: a systematic review and meta-analysis. Surg Endosc. 2023 May;37(5):3340-53. Resumo

258. Ceppa EP, Collings AT, Abdalla M, et al. SAGES/AHPBA guidelines for the use of microwave and radiofrequency liver ablation for the surgical treatment of hepatocellular carcinoma or colorectal liver metastases less than 5 cm. Surg Endosc. 2023 Dec;37(12):8991-9000. Resumo

259. Hall B, Padussis J, Foster JM. Cytoreduction and hyperthermic intraperitoneal chemotherapy in the management of colorectal peritoneal metastasis. Surg Clin North Am. 2017 Jun;97(3):671-82. Resumo

260. Baratti D, Kusamura S, Pietrantonio F, et al. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review. Crit Rev Oncol Hematol. 2016 Jan 22;100:209-22. Resumo

261. Haram A, Boland MR, Kelly ME, et al. The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review. J Surg Oncol. 2017 Jan 20;115(4):470-9. Resumo

262. Min GT, Wang YH, Yao N, et al. The prognostic role of pretreatment platelet-to-lymphocyte ratio as predictors in patients with colorectal cancer: a meta-analysis. Biomark Med. 2016 Dec 5;11(1):87-97. Resumo

263. Tan D, Fu Y, Su Q, et al. Prognostic role of platelet-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2016 Jun;95(24):e3837.Texto completo  Resumo

264. Tsai PL, Su WJ, Leung WH, et al. Neutrophil-lymphocyte ratio and CEA level as prognostic and predictive factors in colorectal cancer: a systematic review and meta-analysis. J Cancer Res Ther. 2016 Apr-Jun;12(2):582-9.Texto completo  Resumo

265. Colloca G, Venturino A, Guarneri D. Neutrophil-to-lymphocyte ratio predicts survival of patients with rectal cancer receiving neo-adjuvant chemoradiation followed by radical resection: a meta-analysis. Expert Rev Anticancer Ther. 2023 Apr;23(4):421-429. Resumo

266. Portale G, Bartolotta P, Azzolina D, et al. Prognostic role of platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte, and lymphocyte-to-monocyte ratio in operated rectal cancer patients: systematic review and meta-analysis. Langenbecks Arch Surg. 2023 Feb 13;408(1):85. Resumo

267. Lin N, Li J, Yao X, et al. Prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer liver metastasis: a meta-analysis of results from multivariate analysis. Int J Surg. 2022 Nov;107:106959.Texto completo  Resumo

268. Zhu L, Dong C, Cao Y, et al. Prognostic role of BRAF mutation in stage II/III colorectal cancer receiving curative resection and adjuvant chemotherapy: a meta-analysis based on randomized clinical trials. PLoS One. 2016 May 3;11(5):e0154795.Texto completo  Resumo

269. Pikoulis E, Margonis GA, Andreatos N, et al. Prognostic role of BRAF mutations in colorectal cancer liver metastases. Anticancer Res. 2016 Sep;36(9):4805-11.Texto completo  Resumo

270. Li ZN, Zhao L, Yu LF, et al. BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Gastroenterol Rep (Oxf). 2020 Jun;8(3):192-205.Texto completo  Resumo

271. Costas-Chavarri A, Nandakumar G, Temin S, et al. Treatment of patients with early-stage colorectal cancer: ASCO resource-stratified guideline. J Glob Oncol. 2019 Feb;5:1-19.Texto completo  Resumo

272. Maak M, Simon I, Nitsche U, et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg. 2013 Jun;257(6):1053-8. Resumo

273. Venook AP, Niedzwiecki D, Lopatin M, et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013 May 10;31(14):1775-81.Texto completo  Resumo

274. Kim HS, Noh GT, Chung SS, et al. Long-term oncological outcomes of robotic versus laparoscopic approaches for right colon cancer: a systematic review and meta-analysis. Tech Coloproctol. 2023 Dec;27(12):1183-9. Resumo

275. Meyers BM, Cosby R, Quereshy F, et al. Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline. Curr Oncol. 2016 Dec 21;23(6):418-24.Texto completo  Resumo

276. Lieu C, Kennedy EB, Bergsland E, et al. Duration of oxaliplatin-containing adjuvant therapy for stage III colon cancer: ASCO clinical practice guideline. J Clin Oncol. 2019 Jun 1;37(16):1436-47.Texto completo  Resumo

277. Kim ST, Kim SY, Lee J, et al. Oxaliplatin (3 months v 6 months) with 6 months of fluoropyrimidine as adjuvant therapy in patients with stage II/III colon cancer: KCSG CO09-07. J Clin Oncol. 2022 Nov 20;40(33):3868-77.Texto completo  Resumo

278. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009 Jul 1;27(19):3109-16.Texto completo  Resumo

279. Baxter NN, Kennedy EB, Bergsland E, et al. Adjuvant therapy for stage II colon cancer: ASCO guideline update. J Clin Oncol. 2022 Mar 10;40(8):892-910.Texto completo  Resumo

280. André T, de Gramont A, Vernerey D, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 2015 Dec 10;33(35):4176-87. Resumo

281. Chibaudel B, Raeisi M, Cohen R, et al. Assessment of the addition of oxaliplatin to fluoropyrimidine-based adjuvant chemotherapy in patients with high-risk stage II colon cancer: an ACCENT pooled analysis. J Clin Oncol. 2024 Dec 10;42(35):4187-95. Resumo

282. Loree JM, Sha A, Soleimani M, et al. Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer. Clin Colorectal Cancer. 2018 Feb 7;17(2):156-63. Resumo

283. Tournigand C, André T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol. 2012 Sep 20;30(27):3353-60. Resumo

284. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010 Jul 10;28(20):3219-26.Texto completo  Resumo

285. Des Guetz G, Nicolas P, Perret GY, et al. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer. 2010 Apr;46(6):1049-55. Resumo

286. Biagi JJ, Raphael MJ, Mackillop WJ, et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer. JAMA. 2011 Jun 8;305(22):2335-42. Resumo

287. Pikouli A, Papaconstantinou D, Wang J, et al. Reevaluating the prognostic role of BRAF mutation in colorectal cancer liver metastases. Am J Surg. 2022 May;223(5):879-83. Resumo

288. Lopez NE, Weiss AC, Robles J, et al. A systematic review of clinically available gene expression profiling assays for stage II colorectal cancer: initial steps toward genetic staging. Am J Surg. 2016 Aug 1;212(4):700-14. Resumo

289. Morton D, Seymour M, Magill L, et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol. 2023 Mar 10;41(8):1541-52.Texto completo  Resumo

290. Clark ME, Smith RR. Liver-directed therapies in metastatic colorectal cancer. J Gastrointest Oncol. 2014 Oct;5(5):374-87.Texto completo  Resumo

291. De Groote K, Prenen H. Intrahepatic therapy for liver-dominant metastatic colorectal cancer. World J Gastrointest Oncol. 2015 Sep 15;7(9):148-52.Texto completo  Resumo

292. Jones C, Badger SA, Ellis G. The role of microwave ablation in the management of hepatic colorectal metastases. Surgeon. 2011 Feb;9(1):33-7. Resumo

293. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2008 Feb 1;26(4):689-90. Resumo

294. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol. 2006 Jan 20;24(3):394-400.Texto completo  Resumo

295. Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017 Jun 20;317(23):2392-401.Texto completo  Resumo

296. Chiorean EG, Nandakumar G, Fadelu T, et al. Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline. JCO Glob Oncol. 2020 Mar;6:414-38.Texto completo  Resumo

297. Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008 Apr 20;26(12):2006-12.Texto completo  Resumo

298. Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol. 2008 Oct;19(10):1720-6.Texto completo  Resumo

299. Marques RP, Duarte GS, Sterrantino C, et al. Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Aug 25;118:54-62. Resumo

300. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007 Oct 20;25(30):4779-86.Texto completo  Resumo

301. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008 Apr 20;26(12):2013-9. Resumo

302. Giantonio BJ, Catalano PJ, Meropol NJ, et al; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007 Apr 20;25(12):1539-44. Resumo

303. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013 Jan;14(1):29-37. Resumo

304. Botrel TE, Clark LG, Paladini L, et al. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2016 Aug 24;16:677.Texto completo  Resumo

305. Pei X, Liu Y, Sun L, et al. Outcome of molecular targeted agents plus chemotherapy for second-line therapy of metastatic colorectal cancer: a meta-analysis of randomized trials. Clin Colorectal Cancer. 2016 Mar 31;15(4):e149-56. Resumo

306. Cremolini C, Antoniotti C, Stein A, et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol. 2020 Aug 20;JCO2001225. Resumo

307. Tang W, Ren L, Liu T, et al. Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases: the BECOME randomized controlled trial. J Clin Oncol. 2020 Sep 20;38(27):3175-84.Texto completo  Resumo

308. Zhu X, Tian X, Yu C, et al. Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: an updated meta-analysis of 12 randomized controlled trials. Medicine (Baltimore). 2016 Aug;95(34):e4232.Texto completo  Resumo

309. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012 Oct 1;30(28):3499-506. Resumo

310. Tabernero J, Yoshino T, Cohn AL, et al; RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015 May;16(5):499-508. Resumo

311. Chen Q, Cheng M, Wang Z, et al. The efficacy and safety of panitumumab plus irinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis. Medicine (Baltimore). 2016 Dec;95(50):e5284.Texto completo  Resumo

312. Heinemann V, Rivera F, O'Neil BH, et al. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. Eur J Cancer. 2016 Sep 1;67:11-20.Texto completo  Resumo

313. Yang YF, Wang GY, He JL, et al. Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: a meta-analysis. Medicine (Baltimore). 2017 Mar;96(12):e6335.Texto completo  Resumo

314. Wang Y, Li X, Huang T, et al. The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trials. World J Surg Oncol. 2023 Oct 26;21(1):340.Texto completo  Resumo

315. Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2017 Feb 6;141(5):625-57.Texto completo  Resumo

316. Pietrantonio F, Cremolini C, Petrelli F, et al. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2015 Jun 5;96(1):156-66. Resumo

317. Modest DP, Karthaus M, Fruehauf S, et al. Panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer: The randomized PANAMA trial (AIO KRK 0212). J Clin Oncol. 2021 Sep 17;JCO2101332.Texto completo  Resumo

318. Watanabe J, Muro K, Shitara K, et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA. 2023 Apr 18;329(15):1271-82.Texto completo  Resumo

319. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014 Oct 23;371(17):1609-18.Texto completo  Resumo

320. Hochster HS, Grothey A, Hart L, et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Ann Oncol. 2014 Jun;25(6):1172-8.Texto completo  Resumo

321. Yalcin S, Uslu R, Dane F, et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results - a Turkish Oncology Group Trial. Oncology. 2013;85(6):328-35.Texto completo  Resumo

322. Simkens LH, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015 May 9;385(9980):1843-52. Resumo

323. Aparicio T, Ghiringhelli F, Boige V, et al. Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9). J Clin Oncol. 2018 Mar 1;36(7):674-81.Texto completo  Resumo

324. Adams RA, Fisher DJ, Graham J, et al. Capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy: results of the randomized FOCUS4-N trial. J Clin Oncol. 2021 Sep 13;JCO2101436.Texto completo  Resumo

325. Ma H, Wu X, Tao M, et al. Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: a meta-analysis. Medicine (Baltimore). 2019 Dec;98(50):e18227.Texto completo  Resumo

326. Xu W, Gong Y, Kuang M, et al. Survival benefit and safety of bevacizumab in combination with erlotinib as maintenance therapy in patients with metastatic colorectal cancer: a meta-analysis. Clin Drug Investig. 2017 Feb;37(2):155-65. Resumo

327. Lo Nigro C, Ricci V, Vivenza D, et al. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. World J Gastroenterol. 2016 Aug 14;22(30):6944-54.Texto completo  Resumo

328. Grothey A, Van Cutsem E, Sobrero A, et al; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):303-12. Resumo

329. Mercier J, Voutsadakis IA. A systematic review and meta-analysis of retrospective series of regorafenib for treatment of metastatic colorectal cancer. Anticancer Res. 2017 Nov;37(11):5925-34.Texto completo  Resumo

330. Røed Skårderud M, Polk A, Kjeldgaard Vistisen K, et al. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a systematic review. Cancer Treat Rev. 2017 Nov 10;62:61-73. Resumo

331. National Institute for Health and Care Excellence. Regorafenib for previously treated metastatic colorectal cancer. Feb 2023 [internet publication].Texto completo

332. Mayer RJ, Van Cutsem E, Falcone A, et al; RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015 May 14;372(20):1909-19.Texto completo  Resumo

333. Prager GW, Taieb J, Fakih M, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023 May 4;388(18):1657-67.Texto completo  Resumo

334. Voutsadakis IA. A systematic review and meta-analysis of trifluridine/tipiracil plus bevacizumab for the treatment of metastatic colorectal cancer: evidence from real-world series. Curr Oncol. 2023 May 24;30(6):5227-39.Texto completo  Resumo

335. Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA. 2018 Jun 26;319(24):2486-96.Texto completo  Resumo

336. ClinicalTrials.gov. ​A study of efficacy and safety of fruquintinib (HMPL-013) in patients with metastatic colorectal cancer (FRESCO-2). Mar 2023 [internet publication].Texto completo

337. Dasari A, Lonardi S, Garcia-Carbonero R, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 Jul 1;402(10395):41-53. Resumo

338. André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020 Dec 3;383(23):2207-18. Resumo

339. Andre T, Amonkar M, Norquist JM, et al. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 May;22(5):665-77. Resumo

340. Diaz LA Jr, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022 May;23(5):659-70. Resumo

341. National Institute for Health and Care Excellence. Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer. May 2005 [internet publication].Texto completo

342. Overman MJ, Lonardi S, Wong KY, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018 Jan 20;36(8):773-9.Texto completo  Resumo

343. ClinicalTrials.gov. Study of induction PD-1 blockade in subjects with locally advanced mismatch repair deficient solid tumors. Oct 2022 [internet publication].Texto completo

344. Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022 Jun 23;386(25):2363-76. Resumo

345. Zhou X, Yao Z, Bai H, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021 Sep;22(9):1265-74. Resumo

346. National Institute for Health and Care Excellence. Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer. Jan 2021 [internet publication].Texto completo

347. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019 Oct 24;381(17):1632-43.Texto completo  Resumo

348. Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023 Jan 5;388(1):44-54.Texto completo  Resumo

349. Kuboki Y, Fakih M, Strickler J, et al. Sotorasib with panitumumab in chemotherapy-refractory KRAS(G12C)-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan;30(1):265-70. Resumo

350. Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023 Dec 7;389(23):2125-39.Texto completo  Resumo

351. Yaeger R, Uboha NV, Pelster MS, et al. Efficacy and safety of adagrasib plus cetuximab in patients with KRASG12C-mutated metastatic colorectal cancer. Cancer Discov. 2024 Jun 3;14(6):982-93.Texto completo  Resumo

352. ClinicalTrials.gov. Phase 1/​2 Study of MRTX849 in patients with cancer having a KRAS G12C mutation KRYSTAL-1. ClinicalTrials.gov Identifier: NCT03785249. Sep 2024 [internet publication]​.Texto completo

353. Raghav K, Siena S, Takashima A, et al. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol. 2024 Sep;25(9):1147-62. Resumo

354. Strickler JH, Cercek A, Siena S, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023 May;24(5):496-508. Resumo

355. Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261-73.Texto completo  Resumo

356. Drilon A, Subbiah V, Gautschi O, et al. Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. J Clin Oncol. 2023 Jan 10;41(2):385-94.Texto completo  Resumo

357. Mocellin S, Baretta Z, Roqué I, et al. Second-line systemic therapy for metastatic colorectal cancer. Cochrane Database Syst Rev. 2017 Jan 27;(1):CD006875.Texto completo  Resumo

358. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008 May 10;26(14):2311-9. Resumo

359. Aldrich J, Pundole X, Tummala S, et al. Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors. Arthritis Rheumatol. 2021 May;73(5):866-74.Texto completo  Resumo

360. Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005 Oct 1;23(28):7125-34.Texto completo  Resumo

361. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013 Sep 12;369(11):1023-34.Texto completo  Resumo

362. Van Cutsem E, Lenz HJ, Köhne CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015 Mar 1;33(7):692-700.Texto completo  Resumo

363. ClinicalTrials.gov. SOX versus XELOX as adjuvant chemotherapy for stage III colorectal cancer patients. ClinicalTrials.gov identifier: NCT03448549. Mar 2020 [internet publication].Texto completo

364. ClinicalTrials.gov. ​A study of botensilimab and balstilimab for the treatment of colorectal cancer. Apr 2023 [internet publication].Texto completo

365. Huang W, Sundquist J, Sundquist K, et al. Use of phosphodiesterase 5 inhibitors is associated with lower risk of colorectal cancer in men with benign colorectal neoplasms. Gastroenterology. 2019 Sep;157(3):672-81.e4.Texto completo  Resumo

366. Cullinane C, Brett A, Devane L, et al. The protective role of phosphodiesterase inhibitors in preventing colorectal cancer and advanced colorectal polyps: a systematic review and meta-analysis. Colorectal Dis. 2023 Oct;25(10):1949-59. Resumo

367. Huang W, Sundquist J, Sundquist K, et al. Phosphodiesterase-5 inhibitors use and risk for mortality and metastases among male patients with colorectal cancer. Nat Commun. 2020 Jun 24;11(1):3191.Texto completo  Resumo

368. Bjørn MX, Perdawood SK. Transanal total mesorectal excision--a systematic review. Dan Med J. 2015 Jul;62(7):A5105.Texto completo  Resumo

369. Lau SYC, Choy KT, Yang TWW, et al. Defining the learning curve of transanal total mesorectal excision: a systematic review and meta-analysis. ANZ J Surg. 2022 Mar;92(3):355-64. Resumo

370. Butterworth JW, Butterworth WA, Meyer J, et al. A systematic review and meta-analysis of robotic-assisted transabdominal total mesorectal excision and transanal total mesorectal excision: which approach offers optimal short-term outcomes for mid-to-low rectal adenocarcinoma? Tech Coloproctol. 2021 Nov;25(11):1183-98. Resumo

371. Townsend AR, Chong LC, Karapetis C, et al. Selective internal radiation therapy for liver metastases from colorectal cancer. Cancer Treat Rev. 2016 Nov;50:148-54. Resumo

372. van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016 May 20;34(15):1723-31.Texto completo  Resumo

373. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004 Nov 1;88(2):78-85. Resumo

374. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001 Dec;12(12):1711-20. Resumo

375. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010 Aug 10;28(23):3687-94.Texto completo  Resumo

376. Mulcahy MF, Mahvash A, Pracht M, et al. Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. J Clin Oncol. 2021 Sep 20;JCO2101839.Texto completo  Resumo

377. d'Andrea E, Russi M, Pacilio M, et al. Yttrium-90 radioembolization of colorectal cancer liver metastases: a systematic review of clinical evidence. Am J Clin Oncol. 2022 Apr 1;45(4):175-81. Resumo

378. Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017 Sep;18(9):1159-71.Texto completo  Resumo

379. Heresbach D, Manfredi S, D'halluin PN, et al. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol. 2006 Apr;18(4):427-33. Resumo

380. Burch JA, Soares-Weiser K, St John DJ, et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen. 2007;14(3):132-7.Texto completo  Resumo

381. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5.Texto completo  Resumo

382. Li X, Fu R, Ni H, et al. Effect of neoadjuvant therapy on the functional outcome of patients with rectal cancer: a systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2023 Feb;35(2):e121-34. Resumo

383. Ryoo SB. Low anterior resection syndrome. Ann Gastroenterol Surg. 2023 Sep;7(5):719-24.Texto completo  Resumo

384. Gebremedhn EG, Shortland PJ, Mahns DA. The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review. BMC Cancer. 2018 Apr 12;18(1):410.Texto completo  Resumo

385. Lee S, Ma C, Shi Q, et al. Potential mediators of oxaliplatin-induced peripheral neuropathy from adjuvant therapy in stage III colon cancer: findings from CALGB (Alliance)/SWOG 80702. J Clin Oncol. 2023 Feb 10;41(5):1079-91.Texto completo  Resumo

386. Stintzing S, Kapaun C, Laubender RP, et al. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer. 2012 Jun 26;132(1):236-45.Texto completo  Resumo

387. Patel SV, Liberman SA, Burgess PL, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the reduction of venous thromboembolic disease in colorectal surgery. Dis Colon Rectum. 2023 Sep 1;66(9):1162-73.Texto completo

388. Emoto S, Nozawa H, Kawai K, et al. Venous thromboembolism in colorectal surgery: incidence, risk factors, and prophylaxis. Asian J Surg. 2019 Sep;42(9):863-73.Texto completo  Resumo

389. Patel SV, Zhang L, Wei XS, et al. A population-based cohort study of venous thromboembolism rates following surgery and during adjuvant chemotherapy in patients with colon cancer. Dis Colon Rectum. 2020 Mar;63(3):336-45.Texto completo  Resumo

390. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: management of immunotherapy-related toxicities [internet publication].Texto completo

391. Hassan C, Antonelli G, Dumonceau JM, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2020. Endoscopy. 2020 Aug;52(8):687-700.Texto completo  Resumo

392. Liu F, Wang LL, Liu XR, et al. Risk factors for radical rectal cancer surgery with a temporary stoma becoming a permanent stoma: a pooling up analysis. J Laparoendosc Adv Surg Tech A. 2023 Aug;33(8):743-9. Resumo

393. Ligibel JA, Bohlke K, May AM, et al. exercise, diet, and weight management during cancer treatment: ASCO Guideline. J Clin Oncol. 2022 Aug 1;40(22):2491-507.Texto completo  Resumo

394. Geng L, Li X, Guo L, et al. The content and effectiveness of physical activity for cancer-related fatigue among colorectal cancer survivors: systematic review and meta-analysis. Nurs Open. 2023 Jul;10(7):4274-85.Texto completo  Resumo

395. Brown JC, Ma C, Shi Q, et al. Physical activity in stage III colon cancer: CALGB/SWOG 80702 (alliance). J Clin Oncol. 2023 Jan 10;41(2):243-54.Texto completo  Resumo

396. Brown JC, Ma C, Shi Q, et al. Inflammation, physical activity, and disease-free survival in stage III colon cancer: cancer and Leukemia Group B-Southwest Oncology Group 80702 (Alliance). J Natl Cancer Inst. 2024 Dec 1;116(12):2032-9.Texto completo  Resumo

397. Veettil SK, Lim KG, Ching SM, et al. Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. BMC Cancer. 2017 Nov 14;17(1):763.Texto completo  Resumo

398. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012 Oct 25;367(17):1596-606.Texto completo  Resumo

399. Dulai PS, Singh S, Marquez E, et al. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. BMJ. 2016 Dec 5;355:i6188.Texto completo  Resumo

400. Hua X, Phipps AI, Burnett-Hartman AN, et al. Timing of aspirin and other nonsteroidal anti-inflammatory drug use among patients with colorectal cancer in relation to tumor markers and survival. J Clin Oncol. 2017 Aug 20;35(24):2806-13. Resumo